Plus Therapeutics, Inc. (PSTV)

Plus Therapeutics' stock price has been volatile, declining by 74.40% over the past year and underperforming relative to the US Biotechs industry and the broader US Market. Key events include a 1-for-25 reverse stock split on March 31, 2026, FDA Orphan Drug Designation for REYOBIQ™ in pediatric malignant gliomas on April 8, 2026, an AMA PLA Code for CNSide® on April 7, 2026, Highmark coverage for CNSide® on April 2, 2026, the appointment of Eric J. Daniels as Chief Development Officer on April 9, 2026, the appointment of Ron Andrews to the Board of Directors on March 26, 2026, and a negative Momentum Indicator on March 12, 2026.

Plus Therapeutics' products and services are not subject to typical consumer demand seasonality. Demand is driven by clinical trials, medical necessity, and cancer research progression.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and precision diagnostics for rare cancers, especially those affecting the central nervous system. Their lead product, REYOBIQ, is in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops drug delivery platforms and offers a molecular diagnostic service, CNSide, through its subsidiary, CNSide Diagnostics, LLC. Another product mentioned is DocePLUS.

Plus Therapeutics is a U.S. clinical-stage pharmaceutical company headquartered in Houston, Texas, with laboratories and clean rooms. The company aims to explore opportunities for geographic expansion beyond the United States.

Plus Therapeutics' brand reputation has been influenced by both positive and negative events. The FDA Orphan Drug Designation and the receipt of an AMA PLA Code and Highmark coverage for CNSide® have enhanced its reputation. However, the decline in stock price and the reverse stock split may have negatively impacted investor confidence.

Plus Therapeutics has a significant number of institutional owners, with 32 institutional owners and shareholders holding 11,565,373 shares. Major institutional shareholders include Vanguard Group Inc., L1 Global Manager Pty Ltd., and BlackRock, Inc. Individual insiders hold approximately 0.405% of the shares, with recent buying activity from Andrew Sims and Robert Lenk.